Migraine Treatment: Evidence-Based Options Explained by an ENT Doctor (2026)

Introduction

Effective migraine treatment has advanced dramatically in the last five years. The arrival of CGRP-targeting therapies, improvements in neuromodulation devices, and a better understanding of lifestyle contributors mean that even people who failed older treatments now have real options. According to the American Migraine Foundation and the US National Institute of Neurological Disorders and Stroke (NINDS), most patients can achieve meaningful control with the right combination of acute medicines, preventive therapy and non-drug strategies.

This evidence-based guide explains every major form of migraine treatment available in the United States, which option fits which patient, what the FDA-approved uses are, common side effects to watch for, and when to escalate to a neurologist or headache specialist. It also covers the practical, insurance-aware steps a US reader can take today.

Core Principles of Migraine Treatment

All modern migraine treatment is built on three principles stated by the American Headache Society (AHS) 2024 consensus:

1. Treat early. Acute medicines work best when taken at the first sign of pain, before central sensitisation sets in.
2. Match treatment to attack severity. Mild attacks may respond to over-the-counter options; moderate to severe attacks usually need a triptan, gepant or ditan.
3. Add preventive therapy early. If attacks occur ≥4 days per month or significantly disrupt life, start preventive treatment rather than only treating individual attacks.

Successful migraine treatment also requires avoiding medication-overuse headache (MOH), which occurs when acute medicines are taken on more than 10–15 days per month and paradoxically worsen the condition.

Acute (Abortive) Migraine Treatment

Acute treatment aims to stop a migraine attack within 2 hours and keep the person pain-free at 24 hours. Options include:

Over-the-counter options

• Ibuprofen 400–600 mg or naproxen sodium 550 mg — effective for mild to moderate attacks.
• Acetaminophen 1000 mg — useful when NSAIDs are contraindicated.
• Combination products (e.g., Excedrin Migraine: acetaminophen + aspirin + caffeine) — FDA-approved for migraine but limit use to avoid rebound.

Antiemetics

Metoclopramide and prochlorperazine treat the nausea of migraine and have independent anti-migraine effects. In US emergency departments they are first-line IV treatments.

Triptans — The Workhorse Class

Triptans are serotonin 5-HT_1B/1D receptor agonists that have anchored migraine treatment since 1991. Seven are FDA-approved: sumatriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan, naratriptan and frovatriptan. Formulations include oral tablets, orally dissolving tablets, nasal sprays and subcutaneous injections.

How to choose a triptan

• Rizatriptan and eletriptan have the highest 2-hour pain-free rates in head-to-head trials.
• Subcutaneous sumatriptan is fastest acting — useful if nausea prevents keeping tablets down.
• Frovatriptan has the longest half-life — useful for menstrual migraine.

Who should avoid triptans

Triptans are contraindicated in uncontrolled hypertension, ischaemic heart disease, prior stroke, Prinzmetal angina and pregnancy (relative). They should not be combined with ergots within 24 hours.

Gepants and Ditans — Newer Acute Options

These newer classes expand migraine treatment for patients who cannot or should not take triptans.

Gepants (small-molecule CGRP antagonists)

• Ubrogepant (Ubrelvy) — FDA-approved 2019 for acute migraine.
• Rimegepant (Nurtec ODT) — FDA-approved for both acute and preventive use (dual indication).
• Zavegepant (Zavzpret) — nasal spray; works in as little as 15 minutes.

Gepants do not constrict blood vessels, so they can be used in people with cardiovascular disease — a major advance over triptans.

Ditans

Lasmiditan (Reyvow) is a serotonin 5-HT_1F agonist with no vasoconstrictor effect. It can cause marked drowsiness, so the FDA label warns against driving for 8 hours after a dose.

Preventive Migraine Treatment

Preventive treatment is indicated when attacks occur on ≥4 days per month, when acute treatment is ineffective or contraindicated, or when attacks are severely disabling. Traditional first-line options recommended by the American Academy of Neurology include:

• Beta-blockers — propranolol, metoprolol, timolol
• Antiepileptics — topiramate, valproate (not in pregnancy)
• Tricyclic antidepressants — amitriptyline
• Candesartan (angiotensin receptor blocker)
• Flunarizine (calcium channel blocker; available in many countries, not US)

Each needs a 2–3 month trial at an adequate dose before deciding whether it works.

Anti-CGRP Monoclonal Antibodies — The Revolution

Four injectable anti-CGRP monoclonal antibodies are FDA-approved for migraine prevention:

• Erenumab (Aimovig) — targets the CGRP receptor; monthly subcutaneous injection
• Fremanezumab (Ajovy) — monthly or quarterly
• Galcanezumab (Emgality) — monthly
• Eptinezumab (Vyepti) — quarterly IV infusion

These medicines reduce monthly migraine days by 50% or more in about half of patients and are generally well tolerated. Common side effects include injection-site reactions and constipation (particularly with erenumab).

Oral atogepant (Qulipta) and dual-use rimegepant (Nurtec ODT) are also FDA-approved for prevention, giving patients a pill option.

Botox for Chronic Migraine

OnabotulinumtoxinA (Botox) is FDA-approved for chronic migraine — defined as headache on ≥15 days per month for more than 3 months, with migraine features on at least 8 of those days. The standard PREEMPT protocol delivers 155 units across 31 injection sites in the head and neck every 12 weeks.

Neuromodulation Devices

Several FDA-cleared devices offer drug-free migraine treatment:

• Nerivio — remote electrical neuromodulation worn on the upper arm; acute and preventive use.
• Cefaly — supraorbital nerve stimulator worn on the forehead; acute and preventive.
• gammaCore — non-invasive vagus nerve stimulator; acute and preventive.
• sTMS (eNeura) — single-pulse transcranial magnetic stimulation.

Lifestyle and Non-Drug Treatment

Lifestyle factors are often the most powerful lever a patient can pull. Evidence supports:

• Consistent sleep — same bedtime and wake-time daily (the SEEDS framework: Sleep, Exercise, Eat, Diary, Stress).
• Hydration — ≥2 litres per day for most adults.
• Regular meals — skipping meals is a top trigger.
• Aerobic exercise — 150 minutes per week reduces migraine frequency.
• Cognitive behavioural therapy (CBT) and biofeedback — Level A evidence for prevention per the AHS.
• Supplements with modest evidence: magnesium (400 mg/day), riboflavin (B2) 400 mg/day, coenzyme Q10 300 mg/day. Discuss these with your clinician before starting.

Vestibular Migraine Treatment — ENT Perspective

Vestibular migraine treatment combines standard migraine prevention (propranolol, topiramate, amitriptyline, anti-CGRP therapies) with vestibular rehabilitation therapy, dietary trigger identification and strict sleep hygiene. Acute vertigo attacks respond partly to antiemetics; triptans have variable benefit for the vertigo component.

Treatment During Pregnancy

Many first-line migraine medicines are not safe in pregnancy. According to the American College of Obstetricians and Gynecologists (ACOG):

• Acetaminophen is generally considered the safest acute option.
• NSAIDs should be avoided after 20 weeks.
• Topiramate and valproate are contraindicated (teratogenic).
• Non-drug options (hydration, rest, biofeedback, Cefaly device) are first choice.
• Discuss triptans with your obstetrician — sumatriptan has the most pregnancy safety data.

Treatment in Children

The American Academy of Neurology recommends:

• For acute attacks: ibuprofen first-line; sumatriptan/naproxen combination, rizatriptan, almotriptan or zolmitriptan nasal are FDA-approved for adolescents.
• For prevention: lifestyle counselling is the strongest evidence base. Many drugs including topiramate showed only modest advantage over placebo in children.

When to See a Specialist

Consider referral to a neurologist or headache specialist if:

• Attacks occur ≥8 days per month despite preventive therapy
• You have failed two preventive medicines at adequate doses
• You suspect vestibular migraine, hemiplegic migraine or chronic migraine
• You need Botox or an anti-CGRP monoclonal antibody
• You are pregnant or planning pregnancy
• There are any red-flag features (sudden severe headache, new neurological signs, headache after 50)

Watch the American Migraine Foundation’s patient video for a visual walkthrough: migraine treatment overview on YouTube.

Frequently Asked Questions

What is the fastest migraine treatment?

Subcutaneous sumatriptan and the nasal zavegepant can relieve pain within 15–30 minutes. Neuromodulation devices work in parallel without drug side effects.

Are anti-CGRP migraine medicines safe long-term?

Current safety data extends to about 6 years. The FDA considers them well tolerated for most adults, though long-term cardiovascular surveillance continues.

Can I take a triptan if I have high blood pressure?

Only if your blood pressure is well-controlled and you have no coronary disease. Gepants or ditans are safer alternatives for cardiovascular patients.

How long until preventive migraine treatment works?

Traditional oral preventives take 8–12 weeks for full effect. Anti-CGRP monoclonal antibodies often show benefit within the first month.

Does Botox cure migraine?

No. Botox reduces monthly headache days in chronic migraine but is not a cure. It is given every 12 weeks indefinitely for responders.

Which migraine treatment is covered by US insurance?

Most plans cover generic triptans and traditional preventives after a prior authorisation. Anti-CGRP therapies and Botox typically require step therapy — documenting failure of two cheaper options first. Manufacturer copay cards can lower out-of-pocket costs significantly.

Summary

Modern migraine treatment combines acute medicines (NSAIDs, triptans, gepants, ditans), preventive therapy (traditional oral drugs, anti-CGRP monoclonal antibodies, Botox for chronic migraine), neuromodulation devices and lifestyle changes using the SEEDS framework. Early treatment, avoiding medication overuse and adding prevention when attacks exceed 4 per month give the best outcomes.

Conclusion

No single migraine treatment works for everyone — but with so many FDA-approved options now available, nearly every patient can find an effective combination. If your current plan is not controlling attacks, work with your primary-care physician on a step-up strategy, and request referral to a neurologist or certified headache specialist if attacks remain disabling. The American Headache Society’s Find a Headache Specialist directory lists US clinicians by state.

References

1. American Headache Society. Consensus Statement: Preventive and Acute Migraine Treatment. Headache, 2024.
2. US Food and Drug Administration. Approved CGRP-Targeting Therapies for Migraine. https://www.fda.gov
3. National Institute of Neurological Disorders and Stroke (NINDS). Migraine Information Page. https://www.ninds.nih.gov
4. Centers for Disease Control and Prevention (CDC). QuickStats on Severe Headache or Migraine. https://www.cdc.gov
5. Dodick DW, et al. Erenumab in Episodic Migraine (STRIVE). NEJM.
6. Lipton RB, et al. Rimegepant for Acute and Preventive Migraine Treatment. NEJM.
7. Blumenfeld A, et al. PREEMPT Protocol for OnabotulinumtoxinA in Chronic Migraine. Headache.
8. American Academy of Neurology. Guideline Update: Pharmacologic Treatment of Pediatric Migraine.
9. Mayo Clinic. Migraine — Diagnosis & Treatment. https://www.mayoclinic.org